Artificial intelligence in drug development: reshaping the therapeutic landscape
Top Cited Papers
Open Access
- 1 January 2025
- journal article
- Published by SAGE Publications in Therapeutic Advances in Drug Safety
- Vol. 16
Abstract
Artificial intelligence (AI) is transforming medication research and development, giving clinicians new treatment options. Over the past 30 years, machine learning, deep learning, and neural networks have revolutionized drug design, target identification, and clinical trial predictions. AI has boosted pharmaceutical R&D (research and development) by identifying new therapeutic targets, improving chemical designs, and predicting complicated protein structures. Furthermore, generative AI is accelerating the development and re-engineering of medicinal molecules to cater to both common and rare diseases. Although, to date, no AI-generated medicinal drug has been FDA-approved, HLX-0201 for fragile X syndrome and new molecules for idiopathic pulmonary fibrosis have entered clinical trials. However, AI models are generally considered “black boxes,” making their conclusions challenging to understand and limiting the potential due to a lack of model transparency and algorithmic bias. Despite these obstacles, AI-driven drug discovery has substantially reduced development times and costs, expediting the process and financial risks of bringing new medicines to market. In the future, AI is expected to continue to impact pharmaceutical innovation positively, making life-saving drug discoveries faster, more efficient, and more widespread.Keywords
This publication has 69 references indexed in Scilit:
- Yersinia pseudotuberculosis mutant OmpF porins with deletions of the external loops: genetic constructions design, expression, isolation and refoldingRussian Journal of Bioorganic Chemistry, 2012
- NNScore 2.0: A Neural-Network Receptor–Ligand Scoring FunctionJournal of Chemical Information and Modeling, 2011
- β3-Adrenoceptor ligand development history through patent reviewExpert Opinion on Therapeutic Patents, 2011
- Tramiprosate in mild-to-moderate Alzheimer’s disease – a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study)Archives of Medical Science, 2011
- Vaccine therapy with dendritic cells transfected with Il13ra2 mRNA for glioma in miceJournal of Neurosurgery, 2010
- Genetic variability and mRNA editing frequencies of the phosphoprotein genes of wild-type measles virusesVirus Research, 2008
- Variations in the H/ACA box sequence of viral telomerase RNA of isolates of CVI988 Rispens vaccineArchives of Virology, 2008
- Zbasic—A novel purification tag for efficient protein recoveryJournal of Chromatography A, 2007
- Zebrafish miR-214 modulates Hedgehog signaling to specify muscle cell fateNature Genetics, 2007
- X-14885A, a novel divalent cation ionophore produced by a Streptomyces culture: discovery, fermentation, biological as well as ionophore properties and taxonomy of the producing culture.The Journal of Antibiotics, 1983